RESEARCH MONOGRAPH · KDC-MN-136

Vasopressin (DDAVP)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

75/100

Workhorse antidiuretic with a memory-modulation history thats more interesting than the current literature suggests

DDAVP (desmopressin) is the deamino-D-arginine modification of vasopressin that selectively retains V2 receptor activity (antidiuretic) while losing most of the V1a vasoconstrictor activity. Made by replacing the N-terminal cysteine amine with deamino and swapping the L-Arg at position 8 for D-Arg. The result is a 12-hour half-life and clean antidiuretic pharmacology, which is why its the standard treatment for central diabetes insipidus and nocturnal enuresis.

The interesting part for research is the historical literature on vasopressin and memory. De Wied and others in the 70s and 80s showed reasonably consistent effects of vasopressin and its fragments on memory consolidation in animal models, with downstream human pilot studies that showed signal in elderly populations and head-injury patients. Most of that program got abandoned when the clinical effects didnt scale and other agents looked more promising commercially. But the underlying neuropeptide-on-memory biology didnt go away; it just stopped being a development priority.

What we like: the peripheral pharmacology is textbook clean. V2-selective, sodium-retention through aquaporin-2 insertion in collecting duct principal cells, well-understood. As a research tool for V2R signaling its a reference compound. The historical memory work is also worth knowing about because it informs how to think about vasopressinergic signaling in CA1 and the lateral septum, which is still an active research area.

What we dont like: the memory literature in humans is small, old, and never really got the well-powered replication treatment. So claims about cognitive effects sit on thinner ground than the peripheral indications. Also DDAVP isnt vasopressin, in the sense that if you're studying V1aR or V1bR effects you need different tools (Manning compound, SR-49059, native AVP).

Mechanism: well-mapped on V2R, less so on the central effects given DDAVP's poor BBB penetration compared to native AVP.

Sourcing: long-established generic pharmaceutical, research-grade is widely available, the deamino and D-Arg modifications are easy to verify by mass and HPLC. This is a forgiving compound to source.

Established workhorse, with a slightly underappreciated history.

Evidence: 88
Mechanism: 82
Reliability: 80
Safety: 78
Sourcing: 85
Value: 70
Signal: 50
Staying power: 70

Plain-language summary Intrigue 60 / 100

Vasopressin (antidiuretic hormone) and the synthetic analog DDAVP (desmopressin) regulate water retention by the kidneys. Used clinically for diabetes insipidus and bedwetting. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous nonapeptide hormone

An endogenous nonapeptide hormone for water retention and vasoconstriction; the synthetic analog desmopressin (DDAVP) is FDA-approved for diabetes insipidus.

Abstract

Vasopressin (arginine vasopressin, AVP, antidiuretic hormone; CAS 113-79-1; molecular weight 1084.23) is an endogenous nonapeptide synthesized in the paraventricular and supraoptic nuclei. The synthetic analog desmopressin (DDAVP; deamino-D-arginine vasopressin) is FDA-approved for diabetes insipidus, primary nocturnal enuresis, hemophilia A, and von Willebrand disease type 1. Mechanism includes V1a (vascular smooth muscle), V1b (pituitary corticotrophs), and V2 (renal collecting duct) receptor agonism. Cognitive enhancement applications historically used intranasal vasopressin (1 to 2 IU intranasally) but the evidence base is weak and current clinical use is largely limited to the approved water-balance and hemostatic indications.

Mechanism of action

V1a/V1b/V2 vasopressin receptor agonist. Antidiuretic and vasoconstrictor effects.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Robertson GL. Vasopressin in osmotic regulation in man. Annu Rev Med 1974.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-136

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Vasopressin (DDAVP)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs